BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of fiscal year 2020 before the market open on Tuesday, April 7, 2020.

PPD, Inc. (Nasdaq:PPD) today announced the cancellation of its fireside chat and related webcast at the Barclays Global Healthcare Conference, previously scheduled for Wednesday, March 11, at 11:45 a.m. (U.S. Eastern Time), as a result of the conference switching to a virtual format. About PPD PPD is a leading global contract research organization providing comprehensive, integrated drug development, labora

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on its clinical development programs.

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported business and financial results for the quarter and year ended December 31, 2019 and provided a corporate update. Recent Corporate Updates In January 2020, the Company contracted with a regional health plan to make its gene expression-based Pigment

TempTraq® single-use, wireless patch ideal for monitoring patient temperatures without need for direct patient contact

-- Adds to Invitae’s competitive advantage by providing rapid answers to patients while further reducing the cost of genetic testing at scale --

Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three and 12 months ended December 31, 2019 and provides a business update.

Following Series of US and European Patent Grants, Cellectis Strengthens its Intellectual Property on CRISPR-Edited T-cell Therapies

Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, announced today that it has commenced an underwritten public offering of $100.0 million of its common stock. Kala also intends to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional